Effect of oral magnesium supplementation on selected cardiovascular risk factors in non-insulin-dependent diabetics
Purvis JR, Cummings DM, Landsman P, Carroll R, Barakat H, Bray J, Whitley C, Horner RD
Archives of family medicine · 24 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 1994-06-01 · Arch Fam Med · vol. 3 · número 6 · págs. 503–508
- Editorial
- American Medical Association
- Citado
- 40 citas · más que el 20% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Magnesium in Health and Disease · Diabetes, Cardiovascular Risks, and Lipoproteins · Magnesium Oxide Properties and Applications
- Palabras clave
- magnesium supplementation, type 2 diabetes, systolic blood pressure, cardiovascular risk factors, serum cholesterol, triglycerides, lipoproteins, erythrocyte magnesium, magnesium chloride, end-organ disease
- MeSH
- humans, diabetic angiopathies, diabetes mellitus, type 2, magnesium deficiency, magnesium chloride, blood glucose, triglycerides, delayed-action preparations, administration, oral, risk factors, blood pressure, adult, aged, aged, 80 and over, middle aged, female, male, cholesterol, ldl, cholesterol, hdl
1 autor
- John R. Purvis🇺🇸 · autor de correspondenciaEast Carolina University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
To evaluate the impact of oral magnesium supplementation on risk factors for end-organ disease in patients with non-insulin-dependent diabetes mellitus (NIDDM).
Design
A 16-week randomized, double-blind, placebo-controlled crossover trial.
Setting
Outpatient center of an academic family medicine residency program.
Patients
Twenty-eight patients (age range, 28 to 84 years; 57.1% black; 85.7% women) with NIDDM controlled by diet and/or an oral hypoglycemic, with a serum cholesterol levels over 5.20 mmol/L (200 mg/dL).
Intervention
Following a 2-week placebo run-in period, each patient was randomized to receive either sustained-release magnesium chloride (Slo-Mag), 384 mg/d, or an identical-appearing placebo for 6 weeks. After a 2-week interim washout period, each patient was then treated with the alternative regimen for an additional 6-week period.
Main outcome measures
The systolic and diastolic blood pressure and levels of serum glucose, low-density and high-density lipoprotein and total cholesterol, triglycerides, and serum and total erythrocyte magnesium were measured at the beginning, midpoint, and end of each 6-week treatment phase.
Results
Systolic blood pressure fell an average of 7.4 mm Hg (P < .05) with treatment. There was no significant change in diastolic blood pressure or levels of serum glucose, low-density and high-density lipoprotein and total cholesterol, triglycerides, or serum and erythrocyte magnesium.
Conclusions
Oral magnesium supplementation in the doses and duration studied is modestly effective in reducing systolic blood pressure in patients with NIDDM but has little impact on other important biochemical parameters related to diabetes-associated end-organ disease.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.